Remission is good - relapse is bad.
作者信息
Gaynon Paul S
机构信息
Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA
出版信息
Haematologica. 2018 Jan;103(1):4-5. doi: 10.3324/haematol.2017.182667.
Abstract
摘要
相似文献
1
Remission is good - relapse is bad.缓解是好的——复发是坏的。
Haematologica. 2018 Jan;103(1):4-5. doi: 10.3324/haematol.2017.182667.
2
Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.复发或难治性费城染色体阳性急性淋巴细胞白血病患儿的挽救治疗
Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26423. Epub 2017 Jan 13.
3
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.成人Ph+急性淋巴细胞白血病采用伊马替尼、化疗和移植的序贯治疗方法：GIMEMA LAL 0904研究的最终结果
Haematologica. 2016 Dec;101(12):1544-1552. doi: 10.3324/haematol.2016.144535. Epub 2016 Aug 11.
4
Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.在费城染色体阳性成人急性淋巴细胞白血病患者中，异基因造血干细胞移植前实现分子缓解：对复发和长期结局的影响
Biol Blood Marrow Transplant. 2016 Nov;22(11):1983-1987. doi: 10.1016/j.bbmt.2016.07.021. Epub 2016 Aug 1.
5
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.费城染色体阳性急性淋巴细胞白血病的治疗
Hematology Am Soc Hematol Educ Program. 2005:118-22. doi: 10.1182/asheducation-2005.1.118.
6
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.甲磺酸伊马替尼联合hyper-CVAD一线治疗成人费城染色体阳性急性淋巴细胞白血病的II期研究最终报告
Haematologica. 2015 May;100(5):653-61. doi: 10.3324/haematol.2014.118588. Epub 2015 Feb 14.
7
Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib.
Hematology. 2007 Dec;12(6):505-9. doi: 10.1080/10245330701384187.
8
10-year complete remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation.一名费城染色体阳性急性淋巴细胞白血病患者使用伊马替尼实现10年完全缓解，未进行高强度化疗或异基因干细胞移植。
Int J Hematol. 2018 Jun;107(6):709-711. doi: 10.1007/s12185-017-2382-2. Epub 2017 Nov 29.
9
Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.新诊断的费城染色体阳性急性淋巴细胞白血病患者接受伊马替尼联合化疗的长期随访。
Am J Hematol. 2015 Nov;90(11):1013-20. doi: 10.1002/ajh.24137. Epub 2015 Oct 12.
10
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).费城染色体阳性急性淋巴细胞白血病（Ph+ ALL）的治疗管理。
Hematology Am Soc Hematol Educ Program. 2009:371-81. doi: 10.1182/asheducation-2009.1.371.
本文引用的文献
1
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.基于免疫球蛋白/T 细胞受体和 BCR/ABL1 方法学，伊马替尼治疗后基于微小残留病灶预测费城染色体阳性急性淋巴细胞白血病的欧洲研究组的诱导治疗后治疗的费城染色体阳性急性淋巴细胞白血病的预测价值。
Haematologica. 2018 Jan;103(1):107-115. doi: 10.3324/haematol.2017.176917. Epub 2017 Oct 27.
2
An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.PCR 在急性淋巴细胞白血病微小残留病监测中的应用进展。
Expert Rev Mol Diagn. 2017 Nov;17(11):953-963. doi: 10.1080/14737159.2017.1377073. Epub 2017 Sep 21.
3
Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.免疫疗法在前体B细胞急性淋巴细胞白血病中的新作用。
Expert Rev Hematol. 2017 Sep;10(9):783-799. doi: 10.1080/17474086.2017.1350165. Epub 2017 Jul 10.
4
Measurable residual disease testing in acute myeloid leukaemia.急性髓系白血病的可测量残留病检测。
Leukemia. 2017 Jul;31(7):1482-1490. doi: 10.1038/leu.2017.113. Epub 2017 Apr 7.
5
Monitoring of childhood ALL using genomic breakpoints identifies a subgroup with CML-like biology.利用基因组断点监测儿童 ALL 可识别出具有 CML 样生物学特性的亚组。
Blood. 2017 May 18;129(20):2771-2781. doi: 10.1182/blood-2016-11-749978. Epub 2017 Mar 22.
6
Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.适应性反应治疗的不同亚型急性淋巴细胞白血病患儿微小残留病的临床影响
Leukemia. 2017 Feb;31(2):333-339. doi: 10.1038/leu.2016.234. Epub 2016 Aug 18.
7
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.异柠檬酸脱氢酶1/2（IDH1/2）而非DNA甲基转移酶3A（DNMT3A）突变是急性髓系白血病患者微小残留病监测的合适靶点：法国急性白血病协会的一项研究
Oncotarget. 2015 Dec 8;6(39):42345-53. doi: 10.18632/oncotarget.5645.
8
Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.外周血微小残留病可能取代骨髓微小残留病成为急性髓系白血病复发的免疫表型生物标志物。
Leukemia. 2016 Mar;30(3):708-15. doi: 10.1038/leu.2015.255. Epub 2015 Sep 16.
9
Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.急性淋巴细胞白血病中的微小残留病诊断：对灵敏、快速且标准化技术的需求。
Blood. 2015 Jun 25;125(26):3996-4009. doi: 10.1182/blood-2015-03-580027. Epub 2015 May 21.
10
Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trial.儿童急性淋巴细胞白血病中枢神经系统复发的结局——ALLR3试验的前瞻性开放队列分析
PLoS One. 2014 Oct 3;9(10):e108107. doi: 10.1371/journal.pone.0108107. eCollection 2014.
Zotero 插件